Journal of Pharmacology and Experimental Therapeutics 2012-01-01

Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases.

Stacie M Bratton, Carrie M Mosher, Farid Khallouki, Moshe Finel, Michael H Court, Jeffery H Moran, Anna Radominska-Pandya

Index: J. Pharmacol. Exp. Ther. 340(1) , 46-55, (2012)

Full Text: HTML

Abstract

Coumadin (R-, S-warfarin) is a challenging drug to accurately dose, both initially and for maintenance, because of its narrow therapeutic range and wide interpatient variability and is typically administered as a racemic (Rac) mixture, which complicates the biotransformation pathways. The goal of the current work was to identify the human UDP-glucuronosyltransferases (UGTs) involved in the glucuronidation of the separated R- and S-enantiomers of 6-, 7-, and 8-hydroxywarfarin and the possible interactions between these enantiomers. The kinetic and inhibition constants for human recombinant 1A family UGTs toward these separated enantiomers have been assessed using high-performance liquid chromatography (HPLC)-UV-visible analysis, and product confirmations have been made using HPLC-mass spectrometry/mass spectrometry. We found that separated R- and S-enantiomers of 6-, 7-, and 8-hydroxywarfarin demonstrate significantly different glucuronidation kinetics and can be mutually inhibitory. In some cases significant substrate inhibition was observed, as shown by K(m), V(max), and K(i), comparisons. In particular, UGT1A1 and extrahepatic UGT1A10 have significantly higher capacities than other isoforms for S-7-hydroxywarfarin and R-7-hydroxywarfarin glucuronidation, respectively. Activity data generated using a set of well characterized human liver microsomes supported the recombinant enzyme data, suggesting an important (although not exclusive) role for UGT1A1 in glucuronidation of the main warfarin metabolites, including Rac-6- and 7-hydroxywarfarin and their R- and S-enantiomers in the liver. This is the first demonstration that the R- and S-enantiomers of hydroxywarfarins are glucuronidated, with significantly different enzymatic affinity and capacity, and supports the importance of UGT1A1 as the major hepatic isoform involved.


Related Compounds

Related Articles:

Investigation of two-dimensional high performance liquid chromatography approaches for reversed phase resolution of warfarin and hydroxywarfarin isomers.

2014-10-10

[J. Chromatogr. A. 1363 , 200-6, (2014)]

Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

2010-05-17

[Chem. Res. Toxicol. 23(5) , 939-45, (2010)]

Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.

2012-09-01

[Drug Metab. Lett. 6(3) , 157-64, (2012)]

Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine.

2015-01-01

[J. Pharm. Sci. 104(1) , 244-56, (2014)]

Development of a method for the analysis of warfarin and metabolites in plasma and urine.

1995-07-01

[Am. Clin. Lab. 14(7) , 20-1, (1995)]

More Articles...